Meta AnalysisID 1422
N-甲基-D-天冬氨酸谷氨酸受体拮抗剂作为具有减轻多巴胺能疗法不良反应特性的抗帕金森病药物的疗效：一项系统评价
CRD42020191488
In Parkinson’s patients receiving dopaminergic therapies, how effective is N-Methyl-D-Aspartate Glutamate Receptor Antagonists in regards to its antiparkinsonian and reductive of side effects properties?
Relationship Network
Interactive first-hop connections across herbs, ingredients, formulas, targets, diseases, symptoms, syndromes, evidence, and monographs.
Click a node to open it in a new tab
Ingredient: 1Meta-analysis: 1Links: 1
Arranging relationship network...
Record Fields
Scalar fields from the final meta_analysis record.
- Meta Analysis Id
- 1422
- Evidence Id
- 9980
- Core Evidence Id
- 9980
- Source Meta Analysis Id
- 1377
- Herb2 Meta Analysis Id
- HBMA001377
- Crd Id
- CRD42020191488
- Title
- Efficacy of N-Methyl-D-Aspartate Glutamate Receptor Antagonists as an Antiparkinsonian agent with reductive properties for adverse effects of dopaminergic therapy; a Systematic Review.
- Review Question
- In Parkinson’s patients receiving dopaminergic therapies, how effective is N-Methyl-D-Aspartate Glutamate Receptor Antagonists in regards to its antiparkinsonian and reductive of side effects properties?
- Study Type Included
- No restrictions on types of study
- Condition Being Studied
- Parkinson's disease is characterized by gradual onset of tremors progressively increasing in severity and may include bradykinesia, muscle rigidity, and loss of automatic movements. A progressive nervous system disorder, which primarily is involved in the reduction in production of dopamine; Parkinson's has no current cure and although some treatments are available for symptoms of the disease.
- Participant
- Patient populations with Parkinson’s disease taking Levaopoda with or without the addition of Carbidopa; and other dopaminergic therapies such as anticholinergics or MAO B inhibitors. Exclusion: Patients with a history of deep brain stimulation, patient populations that are not currently on Parkinson's medication, patient population that do not have Parkinson's
- Animal
- Human Disease Modelled
- Intervention
- N-Methyl-D-Aspartate Glutamate Receptor Antagonists
- Comparator Control
- Common Parkinson's treatments; anticholinergics, COMT inhibitors, etc
- Main Outcome
- efficacy of NMDA receptor antagonists in regards to use as a parkinson treatment/ reduction of adverse symptoms of dopaminergic treatment in Parkinson’s Measures of effect Side effects prevalence
- Outcome Measure
- Additional Outcome
- Not applicable Measures of effect No applicable
- Study Method
- Intervention, Systematic review
- Keyword
- Antiparkinson Agents; Excitatory Amino Acid Antagonists; Humans; N-Methylaspartate; Receptors, N-Methyl-D-Aspartate
- Contact
- Liv Morka [email protected]
- Organisational Affiliation
- Radford University
- Funding Source
- Office of Undergraduate Research and Scholarship; Radford University
- Other Selection Criteria
- Final Publication
- Same Topic Review
- Published Protocol
- Review Type
- Language
- English
- Country
- United States of America
- Review Stage
- Review Ongoing
- First Submission Date
- 2020-06-10
- Registration Date
- 2020-07-10
- Anticipated Start Date
- 2020-06-24
- Anticipated Completion Date
- 2020-08-31
- Title Cn
- N-甲基-D-天冬氨酸谷氨酸受体拮抗剂作为具有减轻多巴胺能疗法不良反应特性的抗帕金森病药物的疗效：一项系统评价
- Title En
- Efficacy of N-Methyl-D-Aspartate Glutamate Receptor Antagonists as an Antiparkinsonian agent with reductive properties for adverse effects of dopaminergic therapy; a Systematic Review.
- Bilingual Status
- complete